Pharma Pricing, Reimbursement & Market Access USA 2024

Know More About Event : 8th Pharma Pricing, Reimbursement & Market Access 2024 “Critical guide for successfully identifying your pricing, reimbursement and market access strategies” 19th – 20th September 2024, Live Casino Hotel, Philadelphia, USA This conference will provide an overview of global pharma pricing, market access systems and cost management techniques, as well as in-depth discussion of some of the most current trends and changes. This conference will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. It will be studied with the help of case studies and industry experiences. Please contact for Sponsor / Delegate at E-mail - kavitha@virtueinsight.co.in or Call- +44-20 3509 3779 SPONSORS: Gold Sponsor - Red Nucleus Consulting Partner - ElevateMIAccess We have more sponsorship opportunities available for the event, which gives you an opportunity to Exhibit/Speak and create brand awareness. DELEGATE REGISTRATION: SUPER EARLY BIRD (Valid Till 15th July 2024) 1 Delegate @ $999 Group Discount @ $1998 (3 Delegates for the price of 2) EARLY BIRD (Valid from16th July 2024)- 19th Aug 2024) 1 Delegate @ $1299 Group Discount @ $2598 (3 Delegates for the price of 2) STANDARD PRICE (Valid from 20th Aug 2024) 1 Delegate @ $1599 Group Discount @ $3198 (3 Delegates for the price of 2) KEY SPEAKERS: DAVID BOWER, Senior Director - U.S. Value & Access – Dermatology, Sanofi Genzyme RODNEY EMERSON, Vice President, Pricing & Contracts, Sandoz NANCY RUSCIO-BELL, VP, Head of US Patient Value & Access, Takeda DINA INVERSO, VP US Market Access, Policy & Reimbursement Lead, GE Healthcare BOXIONG TANG, AVP, Head of HEOR & Medical Value Access, Agenus TOM CROCE, VP, Global Patient Advocacy, Jazz Pharmaceuticals GARY ELLEXSON, Corporate Accounts, Supernus Pharmaceuticals ROBERT ROUSE, Head of Market Access, CSL Behring JASON M. NOTO, Senior VP, US Market Access, AVEO Oncology ALAN POLNARIEV, National Clinical Account Director - VA & DoD, AstraZeneca YONG CHEN, Sr. Director, Real World Evidence, Oncology, Pfizer ANKA G. EHRHARDT, Director, Cell-Based Assays / Analytical Research & Development, Merck JOAQUIN F. MOULD, Global HEOR & Value Strategy Director, CSL Seqirus PETER BARSCHDORFF, Vice President, Deallus YAOZHU (JULIETTE) CHEN, Evidence Strategist, Patient-Centric Developer, Value Solution Leader, AstraZeneca STEPHEN FRAMIL, Corporate Global Head of Accessibility, Merck MARTIN ROST, Former Senior Director, Market Access (Global), Pfizer USMAN IQBAL, Chief Medical Officer, Julz Pharma MARGARET REHAYEM, Former VP, National Alliance of Healthcare Purchaser Coalitions HEATHER LEIGH FLANNERY, CEO & Co-Founder, AI MINDSystems Foundation AYESHA AZAM, Associate Principal, Avalere Health SUSAN THORNTON, CEO, Cutaneous Lymphoma Foundation REED STEPHENS, Partner, Winston & Strawn JOLIE APICELLA, Partner, Wiggin and DanaHEATHER LEIGH FLANNERY, CEO & Co-Founder, AI MINDSystems Foundation CHRISTOPHER H. SCHOTT, Partner, LATHAM & WATKINS Plus more joining soon KEY THEMES: Emerging trends & vision for future Updates – US & EU policy challenges for market access: Stepping ahead Key elements - For successful drug pricing and future guidelines Impact of IRA on strategic pricing and contracting Integrating real-world data into pricing U.S. Inflation Reduction Act, and its implications Successful pricing strategy to widen your market access The new normal: HTA & Reimbursement challenges HTA and decision making in the reimbursement of medicines Staying ahead in the race - Update on pricing and market access in USA, EU & RoW Improve patient access - Accelerating patient access to innovative interventions Are you listening to your patients? Role of patient voice in market access The rise of digital health and value-based healthcare. Impact of AI ML Payer’s perspective – What are they looking for? The international pricing system – What drives parallel trade? Working & staying Connected for better health – Stakeholders / Industry / Payers / Physicians / Patients From PI to Payer to Patient: RWE From the Perspective of Each Key Stakeholder Optimizing market access and commercialization of new drugs through Real-World Evidence Recent regulatory updates & development – Making the best of the situation Implications for companies – What to Prepare for future? Be a part of the networking gathering WHO SHOULD ATTEND: Senior decisions-makers from leading global pharmas, e.g., Senior Director, Executive Director, Senior Vice Presidents and Vice Presidents Senior decisions-makers from mid-size biotech and from mid-size pharmas, e.g., Senior Director, Executive Director, Vice Presidents, and Senior Vice Presidents Content experts from pharma/ life science agencies, consultancies, vendors, with focus on Pricing, Reimbursement, and Market Access Healthcare/ Pharma Payer and Policy decision-makers Industry journalists and industry experts looking for trends and new insights, and to establish new industry contacts Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition.